Xenon Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Xenon Pharmaceuticals Inc. (XENE) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-234.33-182.39-125.37-78.88-28.84-41.60-34.50
Depreciation & Amortization2.562.061.410.910.640.950.59
Deferred Income Tax-8.86-0.29-0.040.06-0.29-0.13-0.11
Stock Based Compensation50.7232.3720.3810.025.680.000.00
Change in Working Capital5.715.90-1.28-2.65-26.0933.520.14
Change in Accounts Receivable-0.610.131.76-0.46-1.030.000.00
Change in Accounts Payable8.533.938.062.972.020.000.00
Change in Other Working Capital1.251.840.82-1.52-0.270.000.00
Other Operating Activities1.25-5.500.8210.740.272.92-4.11
Net Cash from Operating Activities-181.39-151.11-101.03-69.50-48.12-4.71-34.72
Investing Activities
Capital Expenditures-3.08-5.62-2.892.05-2.641.24-0.51
Purchases of Investments-532.27-105.77-551.14-389.47-14.190.000.00
Sales/Maturities of Investments700.34688.14260.63-244.72-14.19-64.97-28.48
Net Cash from Investing Activities165.00-111.39-293.41-246.77-16.82-66.21-28.99
Financing Activities
Common Stock Issued12.08353.52277.77447.28102.5427.40102.85
Other Financing Activities0.050.000.000.000.000.000.00
Net Cash from Financing Activities12.13353.52278.47447.5485.8027.52111.59
Summary
Effect of Forex Changes on Cash-1.670.38-2.48-0.59-0.590.41-0.61
Net Change in Cash-4.2691.40-115.96131.2720.25-43.4147.88
Cash at Beginning of Period148.6457.24175.6945.0124.7667.7520.49
Cash at End of Period142.71-156.7357.24175.6945.0124.7667.75
Free Cash Flow-184.46-156.73-103.92-71.55-50.76-5.95-35.23
Supplemental Disclosures
Interest Paid0.000.000.000.000.340.920.56